TherapeuticsMD
TXMD
94 hedge funds and large institutions have $680M invested in TherapeuticsMD in 2015 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 39 increasing their positions, 20 reducing their positions, and 11 closing their positions.
755% more call options, than puts
Call options by funds: $4.88M | Put options by funds: $571K
118% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 11
95% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 20
61% more capital invested
Capital invested by funds: $422M → $680M (+$258M)
16% more funds holding
Funds holding: 81 → 94 (+13)
0.09% more ownership
Funds ownership: 1.22% → 1.31% (+0.09%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$19M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$11.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.6M |
| 4 |
DM
Deerfield Management
New York
|
+$10.9M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$7.47M |
| 2 |
State Street
Boston,
Massachusetts
|
-$6.07M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.28M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$1.91M |
| 5 |
JG
Jefferies Group
New York
|
-$683K |
TXMD Hedge Fund Activity: Q1 2015 in Review
94 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q1 2015, worth a combined $680M — up 61% from $422M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new TXMD positions and 11 closed out — a net gain of 13 holders — while 39 added to existing stakes and 20 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $19M. The largest seller was RA Capital Management, cutting an estimated $7.47M.
- 94 institutional investors held TherapeuticsMD (TXMD) as of Q1 2015, up from 81 in Q4 2014.
- Funds reported $680M of TherapeuticsMD stock for Q1 2015, up 61% quarter-over-quarter.
- 24 funds opened new TherapeuticsMD positions in Q1 2015 and 11 closed out, a net change of +13 holders.
- The largest TherapeuticsMD buyer in Q1 2015 was T. Rowe Price Associates, an estimated $19M added.
- The largest TherapeuticsMD seller in Q1 2015 was RA Capital Management, an estimated $7.47M sold.
Based on aggregated 13F filings for Q1 2015.